GLAXOSMITHKLINE pushes the boundaries of innovation to bring medicines to market in the shortest timeframe and safest manner possible. It nurtures collaborative partnerships — academic, business, non-profit, and private — to unlock potential in the discovery and manufacturing process of vaccines and transformational medicines. GlaxoSmithKline established a Research and Development (R&D) department that employs 16,000 people across three global businesses — and invested more than $5 bn in 2018. The Fortune-500 company invested along with various collaborators to launch the Medicines Manufacturing Innovation Centre (MMIC) in Scotland. By 2023, the $73m innovation centre will provide high-value R&D employment. The GlaxoSmithKline R&D team at the MMIC will focus on continuous manufacturing and advanced crystallisation, which can drastically reduce market launch times while still meeting strict standards of quality control. The BV judging panel presents GlaxoSmithKline with the 2019 Most Innovative Pharma R&D Team (United Kingdom) award.